The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Open accessAbstract
Chemotherapeutic drugs chronically administered to tumor-bearing mice, using a frequent schedule at doses substantially lower than the maximum tolerated dose (MTD) (i.e., metronomic dosing), can cause sustained and potent antiangiogenic effects by targeting the endothelial cells of newly growing tumor blood vessels. These effects appear to occur in the absence of an increase in the severity of side effects caused by destruction of other cell types normally sensitive to MTD chemotherapy, suggesting a marked and selective sensitivity of activated endothelial cells, the basis of which is unknown. Here we report that protracted exposure of endothelial cells in vitro to low concentrations of several different anticancer agents, including microtubule inhibitors and an alkylating agent, caused marked induction of gene and protein expression of TSP-1, a potent and endothelial-specific inhibitor of angiogenesis. Increases in circulating TSP-1 were also detected in the plasma of human tumor-bearing severe combined immunodeficient mice treated with metronomic low-dose cyclophosphamide. Most importantly, the antiangiogenic and antitumor effects of low-dose continuous cyclophosphamide were lost in TSP-1-null C57BL/6 mice, whereas, in contrast, these effects were retained by using a MTD schedule of the same drug. Taken together, the results implicate TSP-1 as a secondary mediator of the antiangiogenic effects of at least some low-dose metronomic chemotherapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Watnick, R. S., Cheng, Y.-N., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00030-8 · Cited by 318
RetractedLyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationInterferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 873
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
Dawson, D. W., Pearce, S. F. A., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck, N. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.707 · Cited by 676
Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth
Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 540
Self-citationColleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Self-citationLawler, J., Sunday, M., Thibert, V, Duquette, M., George, E. L., Rayburn, H., & Hynes, R. O. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1684 · Cited by 457
Self-citationBocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Self-citationKerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Self-citationRedefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
The cell biology of thrombospondin-1
Chen, H., Herndon, M. E., & Lawler, J. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00107-4 · Cited by 393
Self-citationSlaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Self-citationGuo, N., Krutzsch, H. C., Inman, J. K., & Roberts, D. D. (1997) · PubMed · Cited by 293
Rak, J. W., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria‐Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., & Kerbel, R. S. (2000) · PubMed · Cited by 288
Self-citationSwerlick, R. A., Lee, K. H., Wick, T. M., & Lawley, T. J. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.1.78 · Cited by 282
Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine
Vacca, A., Iurlaro, M., Ribatti, D., Minischetti, M., Nico, B., Ria, R., Pellegrino, A., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v94.12.4143 · Cited by 279
Wang, J., Lou, P., Lesniewski, R., & Henkin, J. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200301000-00003 · Cited by 212
Volpert, O. V., Lawler, J., & Bouck, N. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6343 · Cited by 186
Self-citationThrombospondins and tumor angiogenesis
de Fraipont, F., Nicholson, A. C., Feige, J.-J., & Van Meir, E. G. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02102-5 · Cited by 178
The role of MAPK pathways in the action of chemotherapeutic drugs
Boldt, S. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1831 · Cited by 175
Endothelial progenitor cells as putative targets for angiostatin.
Ito, H., Rovira, I. I., Bloom, M. L., Takeda, K., Ferrans, V. J., Quyyumi, A. A., & Finkel, T. (1999) · PubMed · Cited by 168
Monestiroli, S., Mancuso, P., Burlini, A., Pruneri, G., Dell’Agnola, C., Gobbi, A., Martinelli, G., & Bertolini, F. (2001) · PubMed · Cited by 159
Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics
Reiher, F., Volpert, O. V., Jiménez, B., Crawford, S. E., Dinney, C. P., Henkin, J., Haviv, F., Bouck, N., & Campbell, S. C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10247 · Cited by 133
Capillo, M., Mancuso, P., Gobbi, A., Monestiroli, S., Pruneri, G., Dell’Agnola, C., Martinelli, G., Shultz, L. D., & Bertolini, F. (2003) · PubMed · Cited by 123
Stadheim, T. A., Xiao, H., & Eastman, A. R. (2001) · PubMed · Cited by 74
Francia, G., Mitchell, S., Moss, S. E., Hanby, A. M., Marshall, J. F., & Hart, I. (1996) · PubMed · Cited by 68
Self-citationWolff, J. E. A., Mölenkamp, G., Hotfilder, M., & Laterra, J. (1997) · Klinische Pädiatrie · doi:10.1055/s-2008-1043962 · Cited by 32
Cited by
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Self-citationFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Metadata
- Authors
- Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-10-15
- Volume
- 100
- Issue
- 22
- Pages
- 12917-12922
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2102392974
- Cited by
- 414
- References
- 35
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.